%0 Journal Article
%T Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer
%A Cheol-Kyu Park
%A Ha-Young Park
%A Hong-Joon Shin
%A Hyung-Joo Oh
%A In-Jae Oh
%A Jung-Hwan Lim
%A Ki-Hyun Kim
%A Myung-Geun Shin
%A Soo-Hyun Kim
%A Sung-Chul Lim
%A Yong-Soo Kwon
%A Young-Chul Kim
%A Yu-Il Kim
%J SCIE-indexed Journal
%D 2016
%R 10.21037/jtd.2016.08.72
%X Lung cancer is the most common fatal cancer and its prevalence is increasing in Korea (1-3). Tumor markers have been studied in patients with lung cancer as tools to differentiate lung cancer subtypes and improve diagnosis and treatment selection (4,5). Neuron-specific enolase (NSE) and progastrin-releasing peptide (proGRP) are the most beneficial tumor markers in neuroendocrine tumors, such as small cell lung cancer (SCLC) (6,7). Although NSE was a historically recommended tumor marker for SCLC (8). NSE also stains up to 80% of non-small cell lung cancer (NSCLC) in tissue examinations and is elevated in the serum of 20¨C30% patients with NSCLC (9)
%U http://jtd.amegroups.com/article/view/9104/html